Form 4: Denali Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Denali Therapeutics CEO, Ryan J. Watts, sold shares of company stock to cover tax obligations related to vested restricted stock units.
Summary
- Ryan J. Watts, the President and CEO of Denali Therapeutics, sold a total of 36,916 shares of common stock.
- The sales occurred on January 6, 2025, and January 7, 2025.
- On January 6, 2025, 29,266 shares were sold at a weighted average price of $20.22 per share.
- On January 7, 2025, 7,650 shares were sold at a price of $20.81 per share.
- These sales were made to satisfy tax obligations related to the settlement of previously vested restricted stock units.
- Following these transactions, Mr. Watts directly owns 253,071 shares and indirectly owns 2,202,604 shares through the Watts Family 2015 Trust.
- The direct holdings include 177,940 unvested restricted stock units.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for tax purposes, not indicative of any positive or negative sentiment regarding the company's performance or future prospects.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when restricted stock units vest.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
- Many biotech executives receive a significant portion of their compensation in the form of stock options and restricted stock units.
- Similar transactions are regularly reported by executives at companies like Biogen, Amgen, and Regeneron.
Stakeholder Impact
- The stock sales may have a minor impact on the stock price, but are unlikely to significantly affect long-term shareholders.
- The sales do not indicate any change in the company's operations or strategy.
Key Dates
| Date | Description |
|---|---|
| 01/06/2025 | Sale of 29,266 shares of common stock by Ryan J. Watts. |
| 01/07/2025 | Sale of 7,650 shares of common stock by Ryan J. Watts. |
| 01/08/2025 | Date of signature for the SEC Form 4 filing. |
Keywords
Denali Therapeutics, Ryan J. Watts, stock sale, insider trading, restricted stock units, tax obligations, DNLI
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.